Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus

European Heart Journal

Volumn 21, Issue 1, 2000, Pages 33-38

  Aubo C ^a   Sentí, Mariano ^a   Marrugat, J ^a   Tomas M ^a   Vila, J ^a   Sala, J ^b   Masia R ^b  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Diabetes mellitus; Genetic polymorphism; Myocardial infarction; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HOMOZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SPAIN;

AGED; ARGININE; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CHOLESTEROL; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; ESTERASES; FEMALE; GENOTYPE; GLUTAMINE; HUMANS; HYPERLIPIDEMIAS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC;

EID: 0033987886     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1660     Document Type: Article

References (28)

1. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-4.
2. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33: 498-507.
3. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
4. Ruiz J, Blanche H, James RW et al. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-72.
5. Suehiro T, Nakauchi Y, Yamamoto M et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 1996; 57: 69-73.
6. 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17: 3565-9.
7. Serrato M, Marian AJ. A variant of human paraoxonase/ arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96: 3005-8.
8. Antikainen M, Murtomäki S, Syvänne M et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary heart disease in Finns. J Clin Invest 1996; 98: 883-5.
9. Rice GI, Ossei-Gerning N, Stickland MH, Grant PJ. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron Artery Dis 1997; 8: 677-82.
10. Herrmann S-M, Blanc H, Poirier O et al. The Gin/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 1996; 126: 299-303.
11. Ombres D, Panniteri G, Montali A et al. The Gln-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998; 18: 1611-16.
12. Mackness MI, Harty D, Bhatnagar D et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-9.
13. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1812-18.
14. 192 Arg) is associated with coronary artery disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2257-60.
15. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067-73.
16. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995; 15: 89-95.
17. Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui L-C, Hegele RA. Genetic variation in Paraoxonase-1 and paraoxonase-2 is associated with variation in plasma in Alberta Hutterites. Atherosclerosis 1998; 139: 131-6.
18. Masiá R, Pena A, Marrugat J et al. High prevalence of cardiovascular risk factor in Gerona, Spain, a province with low myocardial infarction incidence. J Epidemiol Community Health 1998; 52: 707-15.
19. Pérez G, Pena A, Sala J, Roset P, Masiá R, Marrugat J. Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in the province of Girona, Spain, 1990 to 1992. Int J Epidemiol 1998; 27: 599-604.
20. Friedewald WT, Levi IR, Fredrickson DS. Estimation of low density lipoprotein cholesterol levels in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
21. Miller SA, Dykes DD, Polesky HF. A Simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1989; 16: 1215.
22. Humbert R, Adler DA, Disteche CM, Hassett C, Omienski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-76.
23. Havel RJ. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation 1990; 81: 694-6.
24. Sentí M, Nogués X, Pedro-Botet J, Rubiés-Prat J, Vidal-Barraquer F. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation 1992; 85: 30-6.
25. Jennings PE, Jones AF, Florkouski CM, Lunec J, Barnett AH. Increased dieneconjugates in diabetic patients with microangiopathy. Diabet Med 1987; 4: 452-6.
26. Aviram M, Billecke S, Sorenson R et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Selective action of human paraoxonase alloenzymes Q and R. Arterioscler Thromb Vasc Biol 1998; 18: 1617-24.
27. Cao H, Girard-Globa A, Berthezene F, Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J Lipid Res 1999; 40: 133-9.
28. Aviram M, Fuhrman B. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Mol Cell Biochem 1998; 188: 149-59.